Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status

MEK inhibition is potentially valuable in targeting KRAS-mutant non-small cell lung cancer (NSCLC). Here, we analyzed whether concomitant LKB1 mutation alters sensitivity to the MEK inhibitor selumetinib, and whether the metabolism drug phenformin can enhance the therapeutic effect of selumetinib in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Zhang, Jun, Nannapaneni, Sreenivas, Wang, Dongsheng, Liu, Fakeng, Wang, Xu, Jin, Rui, Liu, Xiuju, Rahman, Mohammad Aminur, Peng, Xianghong, Qian, Guoqing, Chen, Zhuo G., Wong, Kwok-Kin, Khuri, Fadlo R., Zhou, Wei, Shin, Dong M.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5601710/
https://ncbi.nlm.nih.gov/pubmed/28938614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19779
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki